Amgen is developing MariTide for monthly or quarterly injections, compared with weekly dosing for rival obesity drugs Wegovy and Zepbound. Phase 2 data showed about 20% weight loss, trailing some competitors, while the less-frequent dosing is intended to differentiate the product in the growing obesity market. Amgen has begun Phase 3 trials, with results expected in 2027.
Key facts
Amgen has begun Phase 3 trials of MariTide. source
Amgen expects MariTide Phase 3 trial results in 2027. source
Amgen is developing MariTide, an obesity drug designed for monthly or quarterly injections. source
Amgen's MariTide showed about 20% weight loss in Phase 2 data. source